Current Clinical Staging of Uterine Adenocarcinoma

Introduction to Staging

• The International Federation of Gynecology and Obstetrics (FIGO) recommends the 2009 surgical/pathologic staging system as the standard in clinical practice for uterine adenocarcinoma, with a 2023 update pending broader validation before adoption 1, 2

Staging Criteria

• The 2009 FIGO system emphasizes thorough surgical assessment including histologic grade, myometrial invasion depth, and extent of extrauterine spread, replacing the outdated 1970 clinical staging system which was inaccurate in 15-20% of patients 1, 2
• Stage IA is defined as tumor with <50% myometrial invasion, while Stage IB is defined as tumor with ≥50% myometrial invasion 1, 2
• Stage II involves tumor invasion of cervical stroma, but patients with endocervical glandular involvement without cervical stromal invasion remain classified as Stage I 1, 2
• Stage III includes local/regional spread, with subcategories for tumor invasion of serosa and/or adnexa (IIIA), vaginal and/or parametrial involvement (IIIB), pelvic lymph node involvement alone (IIIC1), and para-aortic lymph node involvement (IIIC2) 1, 2

Key Staging Principles

• Positive peritoneal cytology no longer upstages disease in the 2009 FIGO system, although its importance as an independent risk factor is still considered 1, 2
• Surgical staging must be performed by a multidisciplinary team with expertise in imaging, pathologic evaluation, and surgery, with the extent of staging depending on preoperative and intraoperative assessment 1, 2
• Pathologic nodal assessment informs both stage and adjuvant therapy for apparent uterine-confined endometrial cancer, but can be eliminated if final pathology shows noninvasive endometrioid histology 1, 2

Pathologic Assessment

• Expert pathologic review determines the specific histotype, including endometrioid, serous, clear cell, carcinosarcoma, or undifferentiated/dedifferentiated, with assessment of the uterus, fallopian tubes, ovaries, and peritoneal cytology 1, 2, 3, 4

Common Pitfalls to Avoid

• Avoid upstaging patients based solely on positive peritoneal cytology, as this is no longer part of the staging criteria 1, 2
• Do not classify endocervical glandular involvement without stromal invasion as Stage II, as these patients remain Stage I 1, 2
• Ensure proper distinction between Stage IIIC1 (pelvic nodes only) and IIIC2 (para-aortic involvement), as survival differs significantly 1, 2
• Recognize that clinical staging is inaccurate in 15-20% of cases, making surgical/pathologic staging essential for accurate prognostication 1, 2

FIGO 2009 Staging Criteria for Endometrial Cancer – Stage IA Definition and Clinical Implications

Definition of Stage IA and Stage IB

• Stage IA is defined as tumor confined to the corpus uteri with less than 50 % myometrial invasion. The International Federation of Gynecology and Obstetrics (FIGO) criteria specify this depth threshold for IA classification. 5
• Stage IB is defined as tumor with 50 % or greater myometrial invasion. This cutoff distinguishes IB from IA in the FIGO 2009 system. [5][6]
• In a lesion measuring 0.9 cm of invasion within a total myometrial thickness of 4.7 cm (≈19 % invasion), the tumor meets the <50 % criterion and is therefore staged as IA. 5

Cervical Stromal Invasion

• Stage II requires demonstrable cervical stromal invasion; absence of such involvement excludes a Stage II classification. [5][6]

Role of Lymphovascular Space Invasion (LVSI)

• Positive LVSI does not upstage disease from IA to a higher anatomic stage in the 2009 FIGO system. LVSI is recorded for prognostic purposes but does not alter the stage designation. [5][6]
• LVSI is a critical prognostic factor for risk stratification and treatment planning, yet it does not change the anatomic stage. [5][6]

Risk Stratification and Management Implications for Stage IA with LVSI

• Stage IA tumors with positive LVSI cannot be classified as “low‑risk.” The presence of LVSI automatically moves the case out of the low‑risk category. 5
• Patients with Stage IA and positive LVSI are placed in the intermediate or high‑intermediate risk groups, depending on tumor grade. This risk tier influences subsequent therapeutic decisions. [5][6]
• Risk stratification guides decisions regarding lymph‑node assessment and the need for adjuvant therapy, even though the anatomic stage remains IA. [5][6]

Practical Guidance

• Do not upstage to IB based solely on adenomyosis involvement; measure invasion from the endometrial‑myometrial junction to the deepest tumor point. (Guideline reminder; not a cited fact.)
• Do not conflate risk stratification with staging; LVSI elevates recurrence risk but does not modify the FIGO 2009 stage. [5][6]

Evidence level for the above statements is not explicitly stated in the cited sources.